カテゴリー： Market Monitor Global, 世界, 医療/バイオ

サラセミア治療の世界市場見通し2023年-2029年

◆英語タイトル：Thalassemia Treatment Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8706 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月 ◆ページ数：68 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Thalassemia Treatment Market 調査レポートは次の情報を含め、グローバルにおけるのサラセミア治療市場規模と予測を収録しています。・世界のサラセミア治療市場：売上、2018年-2023年、2024年-2029年
・世界のサラセミア治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のサラセミア治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「DFO」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

サラセミア治療のグローバル主要企業は、Novartis、 Shire PLC、 GlaxoSmithKline、 Johnson & Johnson、 Merck、 Acceleron Pharma、 Bellicum Pharmaceuticals、 Bluebird Bio、 Celgene Corporation、 Gamida Cell、 Incyte Corporation、 Kiadis Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、サラセミア治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のサラセミア治療市場：タイプ別、2018年-2023年、2024年-2029年
世界のサラセミア治療市場：タイプ別市場シェア、2022年
・DFO、DFP、DFX、その他

世界のサラセミア治療市場：用途別、2018年-2023年、2024年-2029年
世界のサラセミア治療市場：用途別市場シェア、2022年
・児童・青少年、大人

世界のサラセミア治療市場：地域・国別、2018年-2023年、2024年-2029年
世界のサラセミア治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるサラセミア治療のグローバル売上、2018年-2023年
・主要企業におけるサラセミア治療のグローバル売上シェア、2022年
・主要企業におけるサラセミア治療のグローバル販売量、2018年-2023年
・主要企業におけるサラセミア治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Novartis、 Shire PLC、 GlaxoSmithKline、 Johnson & Johnson、 Merck、 Acceleron Pharma、 Bellicum Pharmaceuticals、 Bluebird Bio、 Celgene Corporation、 Gamida Cell、 Incyte Corporation、 Kiadis Pharma

*************************************************************

・調査・分析レポートの概要
サラセミア治療市場の定義
市場セグメント
世界のサラセミア治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のサラセミア治療市場規模
世界のサラセミア治療市場規模：2022年 VS 2029年
世界のサラセミア治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのサラセミア治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のサラセミア治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：DFO、DFP、DFX、その他
サラセミア治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：児童・青少年、大人
サラセミア治療の用途別グローバル売上・予測

・地域別市場分析
地域別サラセミア治療市場規模 2022年と2029年
地域別サラセミア治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Novartis、 Shire PLC、 GlaxoSmithKline、 Johnson & Johnson、 Merck、 Acceleron Pharma、 Bellicum Pharmaceuticals、 Bluebird Bio、 Celgene Corporation、 Gamida Cell、 Incyte Corporation、 Kiadis Pharma
...

This report aims to provide a comprehensive presentation of the global market for Thalassemia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Thalassemia Treatment. This report contains market size and forecasts of Thalassemia Treatment in global, including the following market information:
Global Thalassemia Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Thalassemia Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
DFO Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Thalassemia Treatment include Novartis, Shire PLC, GlaxoSmithKline, Johnson & Johnson, Merck, Acceleron Pharma, Bellicum Pharmaceuticals, Bluebird Bio and Celgene Corporation, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Thalassemia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Thalassemia Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Thalassemia Treatment Market Segment Percentages, by Type, 2022 (%)
DFO
DFP
DFX
Others
Global Thalassemia Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Thalassemia Treatment Market Segment Percentages, by Application, 2022 (%)
Children and Teenagers
Adults
Global Thalassemia Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Thalassemia Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Thalassemia Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Thalassemia Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Shire PLC
GlaxoSmithKline
Johnson & Johnson
Merck
Acceleron Pharma
Bellicum Pharmaceuticals
Bluebird Bio
Celgene Corporation
Gamida Cell
Incyte Corporation
Kiadis Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Thalassemia Treatment, market overview.
Chapter 2: Global Thalassemia Treatment market size in revenue.
Chapter 3: Detailed analysis of Thalassemia Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Thalassemia Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Thalassemia Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Thalassemia Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Thalassemia Treatment Overall Market Size
2.1 Global Thalassemia Treatment Market Size: 2022 VS 2029
2.2 Global Thalassemia Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Thalassemia Treatment Players in Global Market
3.2 Top Global Thalassemia Treatment Companies Ranked by Revenue
3.3 Global Thalassemia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Thalassemia Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Thalassemia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Thalassemia Treatment Players in Global Market
3.6.1 List of Global Tier 1 Thalassemia Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Thalassemia Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Thalassemia Treatment Market Size Markets, 2022 & 2029
4.1.2 DFO
4.1.3 DFP
4.1.4 DFX
4.1.5 Others
4.2 By Type – Global Thalassemia Treatment Revenue & Forecasts
4.2.1 By Type – Global Thalassemia Treatment Revenue, 2018-2023
4.2.2 By Type – Global Thalassemia Treatment Revenue, 2024-2029
4.2.3 By Type – Global Thalassemia Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Thalassemia Treatment Market Size, 2022 & 2029
5.1.2 Children and Teenagers
5.1.3 Adults
5.2 By Application – Global Thalassemia Treatment Revenue & Forecasts
5.2.1 By Application – Global Thalassemia Treatment Revenue, 2018-2023
5.2.2 By Application – Global Thalassemia Treatment Revenue, 2024-2029
5.2.3 By Application – Global Thalassemia Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Thalassemia Treatment Market Size, 2022 & 2029
6.2 By Region – Global Thalassemia Treatment Revenue & Forecasts
6.2.1 By Region – Global Thalassemia Treatment Revenue, 2018-2023
6.2.2 By Region – Global Thalassemia Treatment Revenue, 2024-2029
6.2.3 By Region – Global Thalassemia Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Thalassemia Treatment Revenue, 2018-2029
6.3.2 US Thalassemia Treatment Market Size, 2018-2029
6.3.3 Canada Thalassemia Treatment Market Size, 2018-2029
6.3.4 Mexico Thalassemia Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Thalassemia Treatment Revenue, 2018-2029
6.4.2 Germany Thalassemia Treatment Market Size, 2018-2029
6.4.3 France Thalassemia Treatment Market Size, 2018-2029
6.4.4 U.K. Thalassemia Treatment Market Size, 2018-2029
6.4.5 Italy Thalassemia Treatment Market Size, 2018-2029
6.4.6 Russia Thalassemia Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Thalassemia Treatment Market Size, 2018-2029
6.4.8 Benelux Thalassemia Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Thalassemia Treatment Revenue, 2018-2029
6.5.2 China Thalassemia Treatment Market Size, 2018-2029
6.5.3 Japan Thalassemia Treatment Market Size, 2018-2029
6.5.4 South Korea Thalassemia Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Thalassemia Treatment Market Size, 2018-2029
6.5.6 India Thalassemia Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Thalassemia Treatment Revenue, 2018-2029
6.6.2 Brazil Thalassemia Treatment Market Size, 2018-2029
6.6.3 Argentina Thalassemia Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Thalassemia Treatment Revenue, 2018-2029
6.7.2 Turkey Thalassemia Treatment Market Size, 2018-2029
6.7.3 Israel Thalassemia Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Thalassemia Treatment Market Size, 2018-2029
6.7.5 UAE Thalassemia Treatment Market Size, 2018-2029
7 Thalassemia Treatment Companies Profiles
7.1 Novartis
7.1.1 Novartis Company Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Thalassemia Treatment Major Product Offerings
7.1.4 Novartis Thalassemia Treatment Revenue in Global Market (2018-2023)
7.1.5 Novartis Key News & Latest Developments
7.2 Shire PLC
7.2.1 Shire PLC Company Summary
7.2.2 Shire PLC Business Overview
7.2.3 Shire PLC Thalassemia Treatment Major Product Offerings
7.2.4 Shire PLC Thalassemia Treatment Revenue in Global Market (2018-2023)
7.2.5 Shire PLC Key News & Latest Developments
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Company Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Thalassemia Treatment Major Product Offerings
7.3.4 GlaxoSmithKline Thalassemia Treatment Revenue in Global Market (2018-2023)
7.3.5 GlaxoSmithKline Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Thalassemia Treatment Major Product Offerings
7.4.4 Johnson & Johnson Thalassemia Treatment Revenue in Global Market (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 Merck
7.5.1 Merck Company Summary
7.5.2 Merck Business Overview
7.5.3 Merck Thalassemia Treatment Major Product Offerings
7.5.4 Merck Thalassemia Treatment Revenue in Global Market (2018-2023)
7.5.5 Merck Key News & Latest Developments
7.6 Acceleron Pharma
7.6.1 Acceleron Pharma Company Summary
7.6.2 Acceleron Pharma Business Overview
7.6.3 Acceleron Pharma Thalassemia Treatment Major Product Offerings
7.6.4 Acceleron Pharma Thalassemia Treatment Revenue in Global Market (2018-2023)
7.6.5 Acceleron Pharma Key News & Latest Developments
7.7 Bellicum Pharmaceuticals
7.7.1 Bellicum Pharmaceuticals Company Summary
7.7.2 Bellicum Pharmaceuticals Business Overview
7.7.3 Bellicum Pharmaceuticals Thalassemia Treatment Major Product Offerings
7.7.4 Bellicum Pharmaceuticals Thalassemia Treatment Revenue in Global Market (2018-2023)
7.7.5 Bellicum Pharmaceuticals Key News & Latest Developments
7.8 Bluebird Bio
7.8.1 Bluebird Bio Company Summary
7.8.2 Bluebird Bio Business Overview
7.8.3 Bluebird Bio Thalassemia Treatment Major Product Offerings
7.8.4 Bluebird Bio Thalassemia Treatment Revenue in Global Market (2018-2023)
7.8.5 Bluebird Bio Key News & Latest Developments
7.9 Celgene Corporation
7.9.1 Celgene Corporation Company Summary
7.9.2 Celgene Corporation Business Overview
7.9.3 Celgene Corporation Thalassemia Treatment Major Product Offerings
7.9.4 Celgene Corporation Thalassemia Treatment Revenue in Global Market (2018-2023)
7.9.5 Celgene Corporation Key News & Latest Developments
7.10 Gamida Cell
7.10.1 Gamida Cell Company Summary
7.10.2 Gamida Cell Business Overview
7.10.3 Gamida Cell Thalassemia Treatment Major Product Offerings
7.10.4 Gamida Cell Thalassemia Treatment Revenue in Global Market (2018-2023)
7.10.5 Gamida Cell Key News & Latest Developments
7.11 Incyte Corporation
7.11.1 Incyte Corporation Company Summary
7.11.2 Incyte Corporation Business Overview
7.11.3 Incyte Corporation Thalassemia Treatment Major Product Offerings
7.11.4 Incyte Corporation Thalassemia Treatment Revenue in Global Market (2018-2023)
7.11.5 Incyte Corporation Key News & Latest Developments
7.12 Kiadis Pharma
7.12.1 Kiadis Pharma Company Summary
7.12.2 Kiadis Pharma Business Overview
7.12.3 Kiadis Pharma Thalassemia Treatment Major Product Offerings
7.12.4 Kiadis Pharma Thalassemia Treatment Revenue in Global Market (2018-2023)
7.12.5 Kiadis Pharma Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Thalassemia Treatment Market Opportunities & Trends in Global Market
Table 2. Thalassemia Treatment Market Drivers in Global Market
Table 3. Thalassemia Treatment Market Restraints in Global Market
Table 4. Key Players of Thalassemia Treatment in Global Market
Table 5. Top Thalassemia Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Thalassemia Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Thalassemia Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Thalassemia Treatment Product Type
Table 9. List of Global Tier 1 Thalassemia Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Thalassemia Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Thalassemia Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Thalassemia Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Thalassemia Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Thalassemia Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Thalassemia Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Thalassemia Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Thalassemia Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Thalassemia Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Thalassemia Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Thalassemia Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Thalassemia Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Thalassemia Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Thalassemia Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Thalassemia Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Thalassemia Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Thalassemia Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Thalassemia Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Thalassemia Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Thalassemia Treatment Revenue, (US$, Mn), 2024-2029
Table 30. Novartis Company Summary
Table 31. Novartis Thalassemia Treatment Product Offerings
Table 32. Novartis Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Novartis Key News & Latest Developments
Table 34. Shire PLC Company Summary
Table 35. Shire PLC Thalassemia Treatment Product Offerings
Table 36. Shire PLC Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Shire PLC Key News & Latest Developments
Table 38. GlaxoSmithKline Company Summary
Table 39. GlaxoSmithKline Thalassemia Treatment Product Offerings
Table 40. GlaxoSmithKline Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. GlaxoSmithKline Key News & Latest Developments
Table 42. Johnson & Johnson Company Summary
Table 43. Johnson & Johnson Thalassemia Treatment Product Offerings
Table 44. Johnson & Johnson Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Johnson & Johnson Key News & Latest Developments
Table 46. Merck Company Summary
Table 47. Merck Thalassemia Treatment Product Offerings
Table 48. Merck Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Merck Key News & Latest Developments
Table 50. Acceleron Pharma Company Summary
Table 51. Acceleron Pharma Thalassemia Treatment Product Offerings
Table 52. Acceleron Pharma Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Acceleron Pharma Key News & Latest Developments
Table 54. Bellicum Pharmaceuticals Company Summary
Table 55. Bellicum Pharmaceuticals Thalassemia Treatment Product Offerings
Table 56. Bellicum Pharmaceuticals Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Bellicum Pharmaceuticals Key News & Latest Developments
Table 58. Bluebird Bio Company Summary
Table 59. Bluebird Bio Thalassemia Treatment Product Offerings
Table 60. Bluebird Bio Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Bluebird Bio Key News & Latest Developments
Table 62. Celgene Corporation Company Summary
Table 63. Celgene Corporation Thalassemia Treatment Product Offerings
Table 64. Celgene Corporation Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Celgene Corporation Key News & Latest Developments
Table 66. Gamida Cell Company Summary
Table 67. Gamida Cell Thalassemia Treatment Product Offerings
Table 68. Gamida Cell Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Gamida Cell Key News & Latest Developments
Table 70. Incyte Corporation Company Summary
Table 71. Incyte Corporation Thalassemia Treatment Product Offerings
Table 72. Incyte Corporation Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 73. Incyte Corporation Key News & Latest Developments
Table 74. Kiadis Pharma Company Summary
Table 75. Kiadis Pharma Thalassemia Treatment Product Offerings
Table 76. Kiadis Pharma Thalassemia Treatment Revenue (US$, Mn) & (2018-2023)
Table 77. Kiadis Pharma Key News & Latest Developments
List of Figures
Figure 1. Thalassemia Treatment Segment by Type in 2022
Figure 2. Thalassemia Treatment Segment by Application in 2022
Figure 3. Global Thalassemia Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Thalassemia Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Thalassemia Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Thalassemia Treatment Revenue in 2022
Figure 8. By Type - Global Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Thalassemia Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Thalassemia Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 16. US Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 28. China Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Thalassemia Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Thalassemia Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. Novartis Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Shire PLC Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. GlaxoSmithKline Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Johnson & Johnson Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Merck Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Acceleron Pharma Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bellicum Pharmaceuticals Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Bluebird Bio Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Celgene Corporation Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Gamida Cell Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Incyte Corporation Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Kiadis Pharma Thalassemia Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ サラセミア治療の世界市場見通し2023年-2029年(Thalassemia Treatment Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

サラセミア治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp